@article{TCR856,
author = {Fantine N. Giap and Huan B. Giap and Alejandro Mazal and Martin Jermann and Bosco Giap and Richard P. Levy and Erik Blomquist},
title = {Clinical trials for charged particle beam therapy},
journal = {Translational Cancer Research},
volume = {1},
number = {4},
year = {2013},
keywords = {},
abstract = {Since 1954 when the very first patient was treated at Lawrence Berkeley National Laboratory with heavy-charged particles, more than 100,000 patients in total have now been treated with charged particle beam therapy. During the first several decades of this new modality, charged particle beam therapy was accessible only at a small number of institutions. More recently, however, this therapy has become available at a rapidly increasing number of facilities worldwide. This expansion of the discipline has led to the development of many more clinical trials, designed to optimize particle-beam therapy and to compare the results achieved with those resulting from other treatment methods. Presently, more than 50 clinical protocols worldwide are actively involved in the effort to improve our understanding of these clinical guidelines. The purpose of this brief review is to offer a broad overview of these protocols, highlighting the specific disease categories that are now being studied using proton and/or heavier-ion therapy, and how the parameters of dose-escalation, beam conformity, and RBE modeling are being evaluated for various disease sites and stages.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/856}
}